DOCSLIB.ORG

The Two Tondition Multituduhan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Two Tondition Multituduhan THETWO TONDITIONUS 20170266382A1 MULTITUDUHAN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0266382 A1 Dewey et al. (43 ) Pub . Date : Sep . 21, 2017 ( 54 ) SURGICAL INJECTION SYSTEM AND A61F 2 /46 ( 2006 .01 ) METHOD A61B 17 /88 ( 2006 .01 ) (52 ) U . S . CI. (71 ) Applicant : Warsaw Orthopedic , Inc ., Warsaw , IN CPC .. A61M 5 / 19 (2013 .01 ) ; A61B 17 /8825 (US ) ( 2013 . 01 ) ; A61M 5 / 3129 (2013 .01 ) ; A61F (72 ) Inventors : Jonathan M . Dewey , Memphis , TN 2 /4601 ( 2013 . 01 ) ; A61M 2005/ 3128 ( 2013 .01 ) (US ) ; Anthony J . Melkent, Germantown , TN (US ) ; William D . Armstrong, Memphis , TN (US ) ; Daniel (37 ) ABSTRACT A . Shimko , Germantown, TN (US ) ( 21) Appl. No. : 15 /076 ,096 A surgical injection device includes at least one tubular element defining a passageway . The passageway is config ( 22 ) Filed : Mar . 21 , 2016 ured for disposal of a selected volume of an agent and an evacuator disposed within the passageway . An actuator is Publication Classification engageable with the evacuator to entirely expel the selected (51 ) Int. Ci. volume of the agent from the passageway to a selected site . A61M 5 / 19 ( 2006 .01 ) Spinal constructs , implants , systems and methods are dis A61M 5 /31 ( 2006 .01 ) closed . 41N borcunse 122 118 142 suren 120 144 - 166 160 uon voda an vom 116 162 X2 - Guuuuuuuuuuuuuuuuuuuu tour wa More neo min B Noitet oro 148. vomi wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww 244 - wwwwwwwwww www one Von X3 www ng withour wy Woo Ons Trum hvor RUANO WONE umetno am asen 164 249 242 272 1 22768 218 Patent Application Publication Sep . 21 , 2017 Sheet 1 of 12 US 2017 / 0266382 A1 48 VC w one vo orking owodu Wro og AVE womanwoman MI my worden wain wwy Oy a nd are 16 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 08 an w FIG . 1 Show co w O von WA porn wan powing ren any DEW meng Anuman nau WRRLO non wa momous S werden wwwwwww 18 FIG . 2 Sat 82 FIG . 3 FIG . 4 Patent Application Publication _ Sep. 21 , 2017 Sheet 2 Of 12 _ US 2017/ 0266382 41 M?????? , 4 2 3 78??_ q ? :??????? ???????????????????? ? ???? ? ? ? ? ? , 62 43 32 ? ? ? ???????? . & ? 38*????? 4 4 ??????? gia:???? ? ?? ?$ 8 ??? 50 _30 - _ $- ?? f . 6 * ?????????? ??????????????????????????????????????????????? ??????????????????????????? ??????????? ??????????????????????? ?? ? & 68 62 ? ??? ? ? # 2 ? ???3] ?88 32 - - T in ? ?, Patent Application Publication Sep . 21 , 2017 Sheet 3 of 12 US 2017 / 0266382 A1 112 122 118 142 - - 120 LLLLLLLLLLLLLLEEEEEEEEEEEEEEEEE L LLL O com 166 144 - poms - 160 V 144 162 van on X2 DDDD D D my an mono Nothorana von on Kouwen rotus onra 148menonton wiews w 244mm w On mo vor wwwwwww www ON m own X3muntana WDA 7* * sannon we owo worau Qanun JA 164164 242 168 20t 214214 67 227 mm 218 mm FIG . 8 Patent Application Publication Sep . 21 , 2017 Sheet 4 of 12 US 2017 / 0266382 A1 162 I P1 192 116 benecon190 ' ,18wameuws 174 124rema 70wenn 224 172 128com 226 232 228mm beson 2630170 214 150 ing yang C 246 114 146 rrrrrr m242 142 mnnnnnnnnnnnnn 144 148 248m 244- Patent Application Publication Sep . 21 , 2017 Sheet 5 of 12 US 2017 / 0266382 A1 162 mmg 116Persone 192w 182 mon7 164power 178 166 oooooo Arad180 m168 130 FIG.10 or on y sineegge men232 eyond 150 theoriginede wwwwwwwww b B propriaper 214 gyugyugangguanyumas memoriamStarburstunuttuuritius 114 wwwwwwxususiriwiyuuyuru mont 148 242 248mm Patent Application Publication Sep . 21 , 2017 Sheet 6 of 12 US 2017 / 0266382 A1 " nnnnnnnnnn mm162 n ponnnnnnnnnn 130 161merem 192192renom -182 > 164meno ww176 the180 FIG.11 130 urinn 232 150 thing h250 O CM ????????????????????????????? ngangganganyanginginyergrotingonly Wanitarnainnawananhhanggangmatinnhang 214214 114 wantumurcuuuuwwwwwwwwwwwwwwww menggunaangenangnyugyurgy 142 242 148 HER248 Patent Application Publication Sep . 21 , 2017 Sheet 7 of 12 US 2017 / 0266382 A1 314 916m318 912 2201230 344 342 a ce dana 320 328 314 344 BE www yenye 328 326 FIG . 13 bewww. o 357 Rawammoni 326 word trenino 362 318 318 be 314 wwwinan 330 mm estan 314 FIG . 14 FIG . 15 Patent Application Publication Sep . 21 , 2017 Sheet 8 of 12 US 2017 / 0266382 A1 arema cores 344 carem 330 29R SS . WA 366 FIG . 16 362 352 P2 Free 342 sabem V2 344 pro 330 ????????????? Guuu Guuu buduuduuuuuuuuuuuuuuuuuuuuuuuuuuuuuuu 370 mensen * The 372 FIG . 17 Patent Application Publication Sep . 21 , 2017 Sheet 9 of 12 US 2017 / 0266382 A1 320 were342 ZA Formen370 -344 314 372 FIG.18 P2 mwwwpowygwywrwgwyngwyngwygwgwgwgwgwyngwa Ewwertudungcunghucucrcmcrareturnbucubrarwerken 414 352428/ 426 450 432 10 4181 312 CELLULLLLLLLLLLLLLLLLLLLLLL #42 mononnomy mm4X Patent Application Publication Sep. 21, 2017 Sheet 10 of 12 US 2017/ 0266382 A1 5???3: g; , ri ? ?34# 3?????? 42 ,* 37} mugwgwgwgwgwgwyngugugugugugugugugugugu Euwdurduruyorduyurdurdurdurdurduruburbrbrbraucundurdurdurubu ??????????????acao??????????h??n????????????????????son?????en????ni???????o??n ???? ????????????? 4 4 Patent Application Publication _ Sep. 21 , 2017 Sheef 11 0f12 _ US 2017/ 0266382 41 554 ???? 55 ; ?????????? 3 6 ????? ???? ?? ? 532 ?? ? ??& ??????? ??????????????????????????????????????????????????????????????????????????????????????????????????????? ???? ???? ~ ? ??? . $ ?? 3 ? $ } 6 | ? ? $ $ $ ? ? mmmmmmmmm L°PA& ; P . 8 Patent Application Publication Sep . 21 , 2017 Sheet 12 of 12 US 2017 /0266382 A1 570 532 2.Kom3 FAQ?????????? 572 COS 570 532 mm ! Kundeniniwanananananananatilinastusinsinddmammmmmmmmmmragmegmgmmragmamma TURUNUR wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww Bi mmmmmmmmmmmmmmmmm m 3 3 white 558 ben V3 Dongen ES ZLE FIG . 23 US 2017 /0266382 A1 Sep . 21, 2017 SURGICAL INJECTION SYSTEM AND [0012 ] FIG . 7 is a cross section view of the components METHOD shown in FIG . 5 ; [0013 ] FIG . 8 is a perspective view of components of one TECHNICAL FIELD embodiment of a surgical system in accordance with the principles of the present disclosure ; [0001 ] The present disclosure generally relates to medical [0014 ] FIG . 9 is a cross section view of components of one devices for the treatment of musculoskeletal disorders , and embodiment of a surgical system in accordance with the more particularly to a surgical system and a method for principles of the present disclosure ; treating a spine . [0015 ] FIG . 10 is a cross section view of the components shown in FIG . 9 ; BACKGROUND [0016 ] FIG . 11 is a cross section view of the components [ 0002 ] Spinal disorders such as degenerative disc disease , shown in FIG . 9 ; disc herniation , osteoporosis , spondylolisthesis , stenosis , [0017 ] FIG . 12 is a perspective view of components of one scoliosis and other curvature abnormalities , kyphosis , embodiment of a surgical system in accordance with the tumor, and fracture may result from factors including principles of the present disclosure ; trauma, disease and degenerative conditions caused by [0018 ] FIG . 13 is a perspective view of components of one injury and aging . Spinal disorders typically result in symp embodiment of a surgical system in accordance with the toms including pain , nerve damage , and partial or complete principles of the present disclosure ; loss of mobility . [ 0019 ] FIG . 14 is a break away view of components of one [ 0003 ] Non - surgical treatments , such as medication , reha embodiment of a surgical system in accordance with the bilitation and exercise can be effective , however , may fail to principles of the present disclosure ; relieve the symptoms associated with these disorders . Sur - (0020 ] FIG . 15 is a break away view of components of one gical treatment of these spinal disorders includes fusion , embodiment of a surgical system in accordance with the fixation , correction , discectomy, microdiscectomy, corpec principles of the present disclosure ; tomy, decompression , laminectomy, laminotomy, foramin [0021 ] FIG . 16 is a perspective view , with parts separated , otomy, facetectomy and implantable prosthetics . As part of of components of one embodiment of a surgical system in these surgical treatments , spinal constructs including accordance with the principles of the present disclosure ; implants , such as , for example , bone graft , bone fasteners , [0022 ] FIG . 17 is a cross section view of components of spinal rods and interbody devices can be delivered to a one embodiment of a surgical system in accordance with the surgical site for fixation with bone to immobilize a joint. The principles of the present disclosure ; spinal constructs can be used to provide stability to a treated 50023 ] FIG . 18 is a cross section of components of one region and facilitate healing . This disclosure describes an embodiment of a surgical system in accordance with the improvement over these technologies . principles of the present disclosure ; [0024 ] FIG . 19 is a cross section view of the components SUMMARY shown in FIG . 18 ; [0025 ) FIG . 20 is a perspective view of components of one [ 0004 ] In one embodiment, a surgical injection device is embodiment of a surgical system in accordance with the provided . The surgical injection device includes at least one principles of the present disclosure , with parts separated ; tubular element defining a passageway. The passageway is [0026 ] FIG . 21 is a cross section view of components of configured for disposal of a selected volume of an agent and one embodiment of a surgical system in accordance with the an evacuator disposed within the passageway. An actuator is principles of the present disclosure ; engageable with the evacuator to entirely expel the selected [0027 ] FIG . 22 is
Load more

Recommended publications
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,993,540 B2 Haggard Et Al
    US00899.3540B2 (12) United States Patent (10) Patent No.: US 8,993,540 B2 Haggard et al. (45) Date of Patent: Mar. 31, 2015 (54) COMPOSITIONS AND METHODS FOR C08B 37/003: A61L 31/042: A61L 27/58: DELIVERING ANAGENT TO AWOUND A61L 27/20: A61 L 15/28 (75) Inventors: Warren O. Haggard, Bartlett, TN (US); spicion is reopelli" Scott P. Noel, Arlington, TN (US); Joel D. Bumgardner, Memphis, TN (US) (73) Assignee: University of Memphis Research (56) References Cited Foundation, Memphis, TN (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 4,895,724. A * 1/1990 Cardinal et al. .............. 424/418 patent is extended or adjusted under 35 5,541.233 A * 7/1996 Roenigk ......................... 521,54 U.S.C. 154(b) by 42 days. 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (21) Appl. No.: 13/256,585 6,989,157 B2 * 1/2006 Gillis et al. ................... 424,618 7,371.403 B2 5/2008 McCarthy et al. (22) PCT Filed: Mar. 16, 2010 2003, OO15825 A1 1/2003 Sugie et al. 2003/0206958 A1 11/2003 Cattaneo et al. (86). PCT No.: PCT/US2O10/027481 2007/00594.73 A1* 3, 2007 Yamazaki et al. ........... 428/40.1 2009,0004276 A1 1/2009 Ben-Shalom et al. S371 (c)(1), 2009.0075383 A1 3/2009 Buschmann et al. (2), (4) Date: Feb. 27, 2012 FOREIGN PATENT DOCUMENTS (87) PCT Pub. No.: WO2010/107794 EP 1308 177 A1 5, 2003 PCT Pub.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,072,728 B2 Rufo Et Al
    US009072728B2 (12) United States Patent (10) Patent No.: US 9,072,728 B2 Rufo et al. (45) Date of Patent: Jul. 7, 2015 (54) TREATMENT OF SEVERE DISTAL COLITIS FOREIGN PATENT DOCUMENTS (75) Inventors: Paul Rufo, West Roxbury, MA (US); WO WOOO,30626 A2 6, 2000 Wayne I. Lencer, Jamaica Plain, MA WO WO O2/O78648 10, 2002 (US) OTHER PUBLICATIONS (73) Assignee: Children's Medical Center Mimura T. Rizzello F. Helwig U, Poggioli G. Schreiber S. Talbot IC, Corporation, Boston, MA (US) Nicholls RJ. Gionchetti P. Campieri M. and Kamm MA., “Four-week open-label trial of metronidazole and ciprofloxacin for the treatment (*) Notice: Subject to any disclaimer, the term of this of recurrent or refractory pouchitis.” Alimentary Pharmacology & patent is extended or adjusted under 35 Therapeutics, May 2002, 16(5), 909-917.* U.S.C. 154(b) by 1207 days. Tracy JW and Webster LT, Chapter 41 Drugs use in the Chemo therapy of Protozoal Infections (continued)Infections, “Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.” (21) Appl. No.: 10/572,667 Hardman JG, Limbird LE, and Gilman AG, Eds., McGraw-Hill, 2001, 1097-1120 (pp. 1097 and 1105-1108 provided).* (22) PCT Filed: Sep. 20, 2004 Clinicaltrials.gov. Clotrimazole Enemas for Pouchitis in Children and Adults. Aug. 20, 2003.* (86). PCT No.: PCT/US2OO4/O3O813 Olumide F, Adesola AO. Metronidazole retention enema in the man agement of severe intestinal amoebiasis. Niger Med J. Jan. S371 (c)(1), 1976;6(1):2-8 (abstract only provided).* (2), (4) Date: Jan. 13, 2009 Parsad D, Pandhi R.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WO 2016/066256 Al 6 May 2016 (06.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/066256 Al 6 May 2016 (06.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 47/38 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/14 (2006.01) A61K 47/44 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 15/0021 17 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 October 2015 (26.10.201 5) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1419257. 29 October 2014 (29. 10.2014) GB kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JAGOTEC AG [CH/CH]; Eptingerstrasse 61, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, CH-4132 Muttenz (CH).
    [Show full text]
  • Compositions, Methods and Devices for Generating Nanotubes on a Surface
    Michigan Technological University Digital Commons @ Michigan Tech Michigan Tech Patents Vice President for Research Office 6-28-2016 Compositions, methods and devices for generating nanotubes on a surface Craig Richard Freidrich Michigan Technological University, [email protected] Tolou Shokuhfar Michigan Technological University, [email protected] Follow this and additional works at: https://digitalcommons.mtu.edu/patents Recommended Citation Freidrich, Craig Richard and Shokuhfar, Tolou, "Compositions, methods and devices for generating nanotubes on a surface" (2016). Michigan Tech Patents. 131. https://digitalcommons.mtu.edu/patents/131 Follow this and additional works at: https://digitalcommons.mtu.edu/patents US009376759B2 (12) United States Patent (io) Patent No.: US 9,376,759 B2 Friedrich et al. (45) Date of Patent: Jun. 28, 2016 (54) COMPOSITIONS, METHODS AND DEVICES (58) Field of Classification Search FOR GENERATING NANOTUBES ON A None SURFACE See application file for complete search history. (71) Applicant: MICHIGAN TECHNOLOGICAL (56) References Cited UNIVERSITY, Houghton, MI (US) U.S. PATENT DOCUMENTS (72) Inventors: Craig Richard Friedrich, Houghton, 2004/0176828 Al 9/2004 O’Brien MI (US); Tolou Shokuhfar, Houghton, 2009/0014322 A l * 1/2009 Ramarajan et al............ 204/286.1 MI (US) 2009/0093881 Al * 4/2009 Bandyopadhyay ... A61L 27/306 623/16.11 (73) Assignee: Michigan Technological University, (Continued) Houghton, MI (US) FOREIGN PATENT DOCUMENTS ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO 2004/085098 10/2004 U.S.C. 154(b) by 200 days. w o 2011/116085 1/2011 w o 2013/040208 3/2013 (21) Appl.No.: 13/798,287 OTHER PUBLICATIONS (22) Filed: Mar.
    [Show full text]